1.Determination of Naringin in Bogu Pill by HPLC
Traditional Chinese Drug Research & Clinical Pharmacology 1993;0(01):-
Objective To establish a method for the content determination of naringin in Bogu Pill by HPLC. Methods At room temperature and by using ultrasonic extraction, HPLC was performed to determine naringin content on ODS chromatographic column.The mobile phase consisted of a mixture of acetonitrile and 8 % acetic acid (15 ∶ 85)and detection wavelength was at 283 nm.Results The linearity of naringin was in the range of 5.2 ? g / mL~ 31.2 ? g / mL (r=0.9999) and the average recovery was 98.72 % , RSD=1.55 % . Conclusion This method was simple, sensitive and accurate, and can be used for the quality control of Bogu Pill.
2.Determination of Ferulic Acid in Bogu Pill by HPLC
Qixun TANG ; Yanling LI ; Rongzhen PENG ; Yi WU
Traditional Chinese Drug Research & Clinical Pharmacology 2000;0(05):-
Objective To establish a method for the content determination of ferulic acid in Bogu Pill(BP). Methods Ferulic acid was obtained by ultrasonic extraction at room temperature and detected by HPLC. HPLC was performed with ODS chromatographic column, methanol-acetonitrile-1%acetic acid(15: 15: 70) as mobile phase and detection wavelength at 323 nm. Results The linearity of ferulic acid was in the range of 0.56 ?g~11.20 ?g/mL(r=0.9996), and the average recovery was 100.26%, RSD=1.48%. Conclusion This method was efficient and can be used for the quality control of BP.
3.Clinical efficacy of prophylactic cranial irradiation for patients with surgically resected small cell lung cancer
Mengyuan CHEN ; Xiao HU ; Yujin XU ; Ronghua TANG ; Qixun CHEN ; Youhua JIANG ; Jinshi LIU ; Xingming ZHOU ; Weimin MAO ; Ming CHEN
Chinese Journal of Radiation Oncology 2018;27(10):895-899
Objective To evaluate the clinical efficacy of prophylactic cranial irradiation (PCI) in the treatment of surgically resected small cell lung cancer (SCLC).Methods Clinical data of SCLC patients undergoing radical resection surgery in Zhejiang Cancer Hospital from 2003 to 2015 were retrospectively analyzed.According to the treatment modality,all patients were allocated into the PCI and non-PCI groups.A total of 52 patients were finally included,including 19 patients in the PCI group (5 cases of stage Ⅰ,5 stage Ⅱ and 9 stage Ⅲ) and 33 in the non-PCI group (12 cases of stage Ⅰ,5 stage Ⅱ and 16 stage Ⅲ).Kaplan-Meier method was utilized for survival analysis.Cox proportional hazards model was adopted to analyze clinical prognosis.Results The median survival time was 32.9 months in the PCI group,and 20.4 months in the non-PCI group.The 2-year overall survival rate was 72% in the PCI group,significantly higher than 38% in the non-PCI group (P=0.023).The median brain metastasis-free survival (BMFS) was 32.5 months in the PCI group,and 17.1 months in the non-PCI group.In the PCI group,the 2-year BMFS rate was 89%,significantly better than 53% in the non-PCI group (P=0.026).Subgroup analysis demonstrated that PCI could confer survival benefit to patients with p-stage Ⅲ (p=0.031) rather than p-stage Ⅰ (P=0.924) and Ⅱ (P=0.094) counterparts.Multivariate analysis revealed that PCI (HR=0.330,P=0.041) was an independent prognostic factor of the overall survival.Conclusions PCI can reduce thr risk of brain metastasis rate and improve the overall survival of patients with surgically resected SCLC.